The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Targeting SOD1 reduces experimental non–small-cell lung cancer
Open accessAbstract
Approximately 85% of lung cancers are non–small-cell lung cancers (NSCLCs), which are often diagnosed at an advanced stage and associated with poor prognosis. Currently, there are very few therapies available for NSCLCs due to the recalcitrant nature of this cancer. Mutations that activate the small GTPase KRAS are found in 20% to 30% of NSCLCs. Here, we report that inhibition of superoxide dismutase 1 (SOD1) by the small molecule ATN-224 induced cell death in various NSCLC cells, including those harboring KRAS mutations. ATN-224–dependent SOD1 inhibition increased superoxide, which diminished enzyme activity of the antioxidant glutathione peroxidase, leading to an increase in intracellular hydrogen peroxide (H(2)O(2)) levels. We found that ATN-224–induced cell death was mediated through H(2)O(2)-dependent activation of P38 MAPK and that P38 activation led to a decrease in the antiapoptotic factor MCL1, which is often upregulated in NSCLC. Treatment with both ATN-224 and ABT-263, an inhibitor of the apoptosis regulators BCL2/BCLXL, augmented cell death. Furthermore, we demonstrate that ATN-224 reduced tumor burden in a mouse model of NSCLC. Our results indicate that antioxidant inhibition by ATN-224 has potential clinical applications as a single agent, or in combination with other drugs, for the treatment of patients with various forms of NSCLC, including KRAS-driven cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“Also, it is known that oncogenic-driven cancer cells generate increased ROS as byproducts of their augmented metabolism to promote and maintain tumorigenicity (3–5).”
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Mitochondria and cell death: outer membrane permeabilization and beyond
Tait, S. W. G., & Green, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2952 · Cited by 2,593
Wallace, D. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3365 · Cited by 2,404
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 1×
“In fact, studies have shown that disabling antioxidant mechanisms triggers ROS-mediated cell death in a variety of cancer cell types (11–14).”
BackgroundABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G. M., Budinger, G. R. S., & Chandel, N. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003428107 · Cited by 1,742 · cited 1×
“Also, it is known that oncogenic-driven cancer cells generate increased ROS as byproducts of their augmented metabolism to promote and maintain tumorigenicity (3–5).”
Self-citationGriffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683 · cited 1×
“Buthion-ine sulphoximine (BSO) depletes the reduced form of the antioxidant GSH, which is required for GPX activity (35).”
BackgroundNrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 1×
“Proapoptotic B cell lymphoma 2 (BCL2) proteins BAX and BAK induce programmed cell death through caspase 9 (27).”
Thiol chemistry and specificity in redox signaling
Winterbourn, C. C., & Hampton, M. B. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.05.004 · Cited by 1,226
Cited by
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
Self-citationFundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
“Furthermore, recent studies indicate that inhibition of LDH-A leads to the regression of established tumors in genetically engineered mouse models of NSCLC without systemic toxicity (145).”
BackgroundInfluentialSelf-citationSuperoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling
Wang, Y., Branicky, R., Noë, A., & Hekimi, S. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201708007 · Cited by 2,182
Targeting mitochondria metabolism for cancer therapy
Weinberg, S. E., & Chandel, N. S. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1712 · Cited by 1,381
Self-citationOxidative stress inhibits distant metastasis by human melanoma cells
Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., Leitch, A. M., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2015) · Nature · doi:10.1038/nature15726 · Cited by 1,269
Connecting copper and cancer: from transition metal signalling to metalloplasia
Ge, E. J., Bush, A. I., Casini, A., Cobine, P. A., Cross, J. R., DeNicola, G. M., Dou, Q. P., Franz, K. J., Gohil, V. M., Gupta, S., et al. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00417-2 · Cited by 1,298
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
Mitochondrial reactive oxygen species and cancer
Sullivan, L. B., & Chandel, N. S. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-17 · Cited by 786
Self-citationUnderstanding mechanisms of antioxidant action in health and disease
Halliwell, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 629
The Complex Interplay between Antioxidants and ROS in Cancer
Harris, I. S., & DeNicola, G. M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.03.002 · Cited by 626
The Two Faces of Reactive Oxygen Species in Cancer
Reczek, C. R., & Chandel, N. S. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041916-065808 · Cited by 602
“F or p er so na l u se o nl y. non-small-cell lung cancer cells, including those with an oncogenic Kras mutation, through the ROS-dependent activation of the p38/MAPK signaling pathway and the subsequent downregulation of the anti-apoptotic factor myeloid cell leukemia 1 (Glasauer et al. 2014).”
BackgroundSelf-citationMitochondria as playmakers of apoptosis, autophagy and senescence
Abate, M., Festa, A., Falco, M., Lombardi, A., Luce, A., Grimaldi, A., Zappavigna, S., Sperlongano, P., Irace, C., Caraglia, M., et al. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.022 · Cited by 545
ROS in Cancer: The Burning Question
Chio, I. I. C., & Tuveson, D. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.004 · Cited by 532
Oxidative cell death in cancer: mechanisms and therapeutic opportunities
An, X., Yu, W., Liu, J., Tang, D., Yang, L., & Chen, X. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06939-5 · Cited by 523
Targeting antioxidants for cancer therapy
Glasauer, A., & Chandel, N. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.017 · Cited by 499
Self-citationTargeting cuproplasia and cuproptosis in cancer
Tang, D., Kroemer, G., & Kang, R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00876-0 · Cited by 443
Copper metabolism as a unique vulnerability in cancer
Shanbhag, V. C., Gudekar, N., Jasmer, K., Papageorgiou, C., Singh, K., & Petris, M. J. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118893 · Cited by 368
Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling
Luo, M., Shang, L., Brooks, M. D., Jiagge, E., Zhu, Y., Buschhaus, J. M., Conley, S., Fath, M. A., Davis, A., Gheordunescu, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.006 · Cited by 358
Ramchandani, D., Berisa, M., Tavarez, D. A., Li, Z., Miele, M., Bai, Y., Lee, S. B., Ban, Y., Dephoure, N., Hendrickson, R. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27559-z · Cited by 309
Superoxide dismutase: An updated review on its health benefits and industrial applications
Islam, M. N., Rauf, A., Fahad, F. I., Emran, T. B., Mitra, S., Olatunde, A., Shariati, M. A., Rebezov, M., Rengasamy, K. R. R., & Mubarak, M. S. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1913400 · Cited by 307
Dissecting Redox Biology Using Fluorescent Protein Sensors
Schwarzländer, M., Dick, T. P., Meyer, A. J., & Morgan, B. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6266 · Cited by 304
ROS-modulated therapeutic approaches in cancer treatment
Raza, M. H., Siraj, S., Arshad, A., Waheed, U., Aldakheel, F., Alduraywish, S., & Arshad, M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2464-9 · Cited by 297
Expanding roles of superoxide dismutases in cell regulation and cancer
Che, M., Wang, R., Li, X., Wang, H.-Y., & Zheng, X. F. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.001 · Cited by 270
Cancer, Oxidative Stress, and Metastasis
Gill, J. G., Piskounova, E., & Morrison, S. J. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030791 · Cited by 266
Mitochondria Targeting as an Effective Strategy for Cancer Therapy
Ghosh, P., Vidal, C., Dey, S., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093363 · Cited by 263
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
“SOD1 inhibitor ATN-224 increases levels of peroxide, activates p38 pathway, and decreases levels of anti-apoptotic protein Mcl1, inducing regression of tumors in a mouse model of NSCLC [198].”
BackgroundSOD1, an unexpected novel target for cancer therapy.
Papa, L., Manfredi, G., & Germain, D. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.4 · Cited by 147
“Further, their study reported that this elevation in hydrogen peroxide leads to activation of p38 and a decrease in the anti-apoptotic factor MCL1 [45], suggesting that inhibition of SOD1 induces cell death by apoptosis.”
BackgroundInfluential
Metadata
- Authors
- Glasauer, A., Sena, L. A., Diebold, L. P., Mazar, A. P., & Chandel, N. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-12-02
- Volume
- 124
- Issue
- 1
- Pages
- 117-128
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2096752472
- Cited by
- 212
- References
- 15
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.